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ABSTRACT  
Drug-induced acute kidney injury (AKI) is often encountered in hospitalized patients. Although 
serum creatinine (SCr) is still routinely used for assessing AKI, it is known to be insensitive and 
nonspecific. Therefore, our objective was to evaluate kidney injury molecule 1 (KIM-1) in 
conjunction with microRNA (miR)-21, -200c, and -423 as urinary biomarkers for drug-induced 
AKI in humans. 
In a cross-sectional cohort of patients (n=135) with acetaminophen (APAP) overdose, all four 
biomarkers were significantly (p<0.004) higher not only in APAP-overdosed patients with AKI 
(based on SCr increase) but also in APAP-overdosed patients without clinical diagnosis of AKI 
compared to healthy volunteers. In a longitudinal cohort of patients with malignant 
mesothelioma receiving intraoperative cisplatin (Cp) therapy (n=108) the four biomarkers 
increased significantly (p<0.0014) over time after Cp administration, but could not be used to 
distinguish patients with or without AKI. Evidence for human proximal tubular epithelial cells 
(HPTECs) being the source of miRNAs in urine was obtained first, by in situ hybridization based 
confirmation of increase in miR-21 expression in the kidney sections of AKI patients and 
second, by increased levels of miR-21, -200c and -423 in the medium of cultured HPTECs 
treated with Cp and 4-aminophenol (APAP degradation product). Target prediction analysis 
revealed 1102 mRNA targets of miR-21, -200c and -423 that are associated with pathways 
perturbed in diverse pathological kidney conditions. In summary, we report non-invasive 
detection of AKI in humans by combining the sensitivity of KIM-1 along with mechanistic 
potentials of miR-21, -200c and -423.  
 
KEYWORDS 
Nephrotoxicity in Patients, Biomarker, Acute Kidney Injury, microRNAs, KIM-1 
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INTRODUCTION  
Acute Kidney Injury (AKI) affects 1 in 5 hospitalized patients worldwide (Susantitaphong et al., 
2013). A substantial proportion of AKI is attributed to drug-induced kidney injury (DIKI): 18-27% 
in hospitalized individuals with AKI (Taber and Pasko, 2008;  Uchino et al., 2005). Furthermore, 
nephrotoxicity is a common reason for drug development failure both in the preclinical and 
clinical stages. In clinical settings, AKI is assessed by measurement of functional biomarkers 
like serum creatinine (SCr) that is known to have low sensitivity, specificity, and limited 
capability for early diagnosis (Vaidya et al., 2008). A delayed diagnosis hinders not only timely 
care of AKI patients but also prevents stratification of AKI patients for clinical trials of AKI 
treatment; therefore, there is an urgent need for new kidney injury biomarkers with improved 
characteristics.  
In 2008, seven urinary protein biomarkers were amongst the first batch qualified by the United 
States Food and Drug Administration (FDA) and European Medicines Agency (EMA, 2009) for 
the assessment of DIKI in preclinical studies. Although these biomarkers, like Kidney injury 
molecule-1 (KIM-1), outperformed traditional biomarkers in sensitivity and specificity in 
preclinical studies, successful regulatory qualification and implementation into clinical practice 
are still awaited (Dieterle and Sistare, 2010;  Jensen, 2004; Murray et al., 2014). Another class 
of biomarkers that have recently emerged as promising candidates for detection of diverse 
cancer types, organ damages and other disease states are extracellular microRNAs (miRNAs) 
found stable in diverse body fluids and resistant to RNase-mediated degradation, pH variability 
and multiple freeze- thaw cycles (McDonald et al., 2011;  Mitchell et al., 2008;  Mraz et al., 
2009;  Weber et al., 2010).  MiRNAs are approximately 20-25 nucleotides long, non-coding and 
evolutionarily conserved small RNAs that function intracellularly as post-transcriptional 
regulators of gene expression by binding to complementary sequences in the 3'-untranslated 
regions of target mRNAs (Krol et al., 2010). Our group described the methodology and 
application for the use of urinary miRNAs to differentiate AKI patients from healthy individuals 
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(Ramachandran et al., 2013;  Saikumar et al., 2012). In particular, we found urinary levels of 
miR-21, miR-200c and miR-423 exhibited significantly high sensitivity and specificity in 
differentiating AKI patients admitted in the intensive care unit vs. patients with no evidence of 
AKI (Ramachandran, et al., 2013).  
The objective here was to evaluate the performance of KIM-1, miR-21, miR-200c and miR-423 
for detecting drug-induced AKI in humans. Specifically the aims were: 1) to measure urinary 
KIM-1, miR-21, miR-200c and miR-423 in a cross-sectional cohort of patients (n=135) with 
acetaminophen (APAP) overdose and in a longitudinal cohort of patients (n=108) with malignant 
mesothelioma receiving cytoreductive surgery with intraoperative cisplatin therapy; 2) to identify 
the source of the miRNAs by performing in situ hybridization in human kidney sections and by 
conducting in vitro experiments using human proximal tubular epithelial cells following toxicity; 
and 3) to computationally predict the targets for the three candidate miRNAs and highlight the 
possibility of urinary miRNA profiles to reflect pathological events in the kidney.  
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MATERIALS & METHODS 
Patients and Samples 
All participants were patients or healthy volunteers recruited at the Brigham and Women’s 
Hospital Boston, MA, or at the MRC Centre for Drug Safety Science, University of Liverpool, 
UK. The Institutional Review Board of both institutions approved the protocols for recruitment 
and sample collection, which was performed with informed consent of the participants. 
Acetaminophen cohort: Urine samples from healthy volunteers (n=65) and a cross-sectional 
study of individuals with acetaminophen (APAP) overdose (n=70) were enrolled from the MRC 
Centre for Drug Safety Science BIOPAR NHS portfolio study. Approximately 60% of the APAP 
overdosed patients (n=43) had AKI defined by serum creatinine (SCr) concentrations >1 mg/dl.  
Cisplatin Mesothelioma cohort: Urine samples were collected at the Brigham and Women’s 
Hospital as part of a longitudinal study enrolling patients with malignant mesothelioma 
undergoing cytoreductive surgery with intraoperative heated cisplatin chemotherapy (n=108). 
Sampling was performed prior therapy (Pre) and on nine subsequent time points: 4h, 8h, 12h, 
24h, 48h, 72h, 96h, 120h and 144h. Approximately 40% of the patients developed AKI (AKI 
Stage 1, AKI Stage 2&3) defined by Acute Kidney Injury Network (AKIN) criteria (Mehta et al., 
2007) at any time point. From the 108 enrolled patients, two were excluded because of 
incomplete data sets. 
Biopsy samples: Paraffin embedded kidney tissue samples were obtained from Brigham and 
Women Hospital’s Pathology department. The biopsy was performed in patients to ascertain a 
clinical diagnosis of acute tubular necrosis after allograft rejection (n=3). For comparison, kidney 
biopsy samples diagnosed as within normal limits (n=3) were also included. 
 
Urine Collection and Analysis 
Urine was collected from spontaneous voids or from indwelling Foley catheters followed by 
centrifugation at 3,000xg for 10 minutes and microscopic examination of the urine sediment 
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(Olympus microscope). The urine supernatant was aliquoted and frozen within 4h of collection 
at -80°C. No additives or protease inhibitors were added. Urinary creatinine concentrations were 
measured utilizing the commercially available Creatinine (urinary) Colorimetric Assay from 
Cayman Chemical (Ann Arbor, MI). Using the Magnetic Luminex® Performance Assay (Human 
Kidney Biomarker Base Kit in conjunction with the Human TIM-1/KIM-1/HAVCR Kit; R&D 
Systems, Minneapolis, MN), KIM-1 was measured in 50 µl urine supernatant according to the 
manufacturer’s instructions on a Bio-plex 200 (Bio-Rad; Hercules, CA). KIM-1 concentrations 
(pg/ml) were normalized to urinary creatinine (UCr; mg/dl) to account for dilution effects of the 
hydration status and are reported as urinary levels in pg/mg UCr. 
 
In vitro Experiments 
Human proximal tubular epithelial cells (HPTECs) which are passaged cells derived from 
normal human kidney tissue were purchased from Biopredic International (Rennes, France). 
Previously, we have shown that HPTECs possess characteristics of differentiated epithelial 
cells, such as polar architecture, junctional assembly, expression and activity of transporters, 
ability to synthesize enzymes like glutathione and γ-glutamyl transferase all up to passage 4 
(Adler, et al., 2015). Thus we consider them to be not only primary cells but also better than the 
immortalized cells derived from human (HK2), dog (MDCK) and pig (LLCPK1) in terms of 
mimicking human kidney tubular epithelial structure and function. The cells were cultured in 
DMEM/Hams-F12 with GlutaMAX medium supplemented with 100 IU/ml penicillin, 100 µg/ml 
streptomycin, 36 ng/ml hydrocortisone, 10 ng/m epidermal growth factor, 1% insulin-transferrin-
selenium and 4 pg/ml triiodothyronin on collagen coated tissue culture plates at 37°C in a 
humidified 5% CO2
 incubator. Cp and 4-aminophenol (Sigma-Aldrich; Saint Louis, MO) were 
diluted in medium with 0.5% DMSO with final concentrations of 10 µM to 1000 µM for dose-
response experiments in 96-well plates. After 24h cell viability was measured by Cell-Titer Glow 
assays (Promega; Madison, WI) and dose-response curves were generated using GraphPad 
Page 6 of 36Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 7 of 31
Prism 6 (GraphPad Software Inc.; La Jolla, CA). Calculated LD50 values correspond to 
previously published for these compounds and cells (Adler, et al., 2015). For measurement of 
miRNAs in medium and in the cells itself, HPTECs were seeded in 6-well plates and treated 
with 85 and 100 µM Cp and 4-aminophenol, concentrations selected based on previously 
published LD50 values. After 24h of treatment, medium was removed, centrifuged twice (10 min 
1,600xg then 10 min 16,000xg) and the resulting supernatant as well as the corresponding cells 
were used for total RNA isolation. 
 
RNA Isolation and Measurement of miRNAs  
RNA isolation: 200 µl urinary supernatant was used for isolation with the miRNeasy 
Serum/Plasma Kit from Qiagen (Valencia, CA) according to manufacturer’s instructions. Total 
RNA form 200 µl medium supernatant and HPTECs was isolated with the miRNeasy Mini Kit 
(Qiagen).  Quality and quantity of the cellular RNA war assessed photometrically using a 
NanoDrop 8000 (Thermo Scientific; Wilmington, DE). 
Reverse transcription (RT) and Pre-Amplification: 1.5 µl of the eluted RNA (urinary and medium 
supernatant) or 10 ng cellular RNA were revers transcribed into cDNA using Qiagen’s miScript 
RTII kit. The prepared cDNA was diluted five-fold and 5 µl of the diluted cDNA was then pre-
amplified with Qiagen’s miScript PreAMP kit for urinary and medium samples. The pre-amplified 
cDNA was diluted five-fold prior to qPCR detection.  
qPCR: For urine samples, candidate miRNA evaluation was performed using custom 384-well 
plates preloaded with specific primer probes for miR-21, -200c and -423 from Qiagen. For 
medium and cellular miRNAs same assays were used. This SYBR Green-based qPCR was 
performed according to manufacturer’s instructions with 2 µl diluted and pre-amplified cDNA in a 
total reaction volume of 10 µl. The thermal profile was as following: activation 15 sec at 95°C; 
40 cycles of annealing/elongation with 15 sec at 94°C, 30 sec at 60°C and 30 sec at 72°C. 
Finally, a melt curve analysis war included. For urine samples, the Ct of the positive qPCR 
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control was subtracted from the Ct of the miRNA to get a ∆Ct value for each sample. These ∆Ct 
values were converted to linear scale by computing 2-∆Ct and normalized to UCr to calculate 
arbitrary urinary levels for each miRNA per sample (2-∆Ct/UCr). Medium and cellular miRNAs 
were normalized to the positive qPCR control and let-7f, respectively, according to the ∆∆Ct 
method for calculating relative quantities (RQ, 2-∆∆Ct). 
In situ Hybridization 
Kidney biopsy samples were fixed in neutral buffered formalin, trimmed and paraffin embedded 
followed by sectioning of the tissue block into approximately 5 µm thick sections. Standard H&E 
staining was used to assess the degree of injury. In situ hybridization was performed using 
double-digoxigenin labeled miRNA probes from Exiqon (Vedbaek, Denmark) according to the 
manufacturer’s instructions. For hybridization, miRNA probes (miR-21-5p: 
TCAACATCAGTCTGATAAGCTA, Tm 83°C, 60 nM; miR-200c-3p: 
TCCATCATTACCCGGCAGTATTA, Tm 87°C, 80 nM; miR-423-5p: 
AAAGTCTCGCTCTCTGCCCCTCA, Tm 94°C, 60 nM) were incubated for one hour 30°C below 
the RNA melting temperature which corresponds to the optimal hybridization temperature. 
Nuclear Fast RedTM was used for counter staining (Sigma-Aldrich). Finally, sections were 
analyzed by light microscopy.  
 
Target analysis 
Ingenuity Pathway Analysis (IPA, Ingenuity® Systems, www.ingenuity.com) was employed to 
search for target mRNAs containing sequences complementary to those present in the miRNAs 
(so-called miRNA target analysis for identification of mRNAs potentially regulated by miRNAs) 
and for pathway analysis in general. The two following filter criteria were applied for target 
analysis: 1.) experimentally observed and/or highly predicted target relation, i.e. sequence 
complementarity between mRNA and miRNA, and 2.) known expression in the kidney. The final 
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group of identified miRNA targets was further investigated with IPA’s Core Analysis to find 
associated pathways and diseases. 
 
Statistical analysis  
Urinary levels of miRNAs and KIM-1 are expressed as median and interquartile range with 5th 
and 95th percentiles as whiskers. Statistical significance was calculated with log2 urinary levels 
by t-test considering a p-value cut-off adjusted for multiple comparisons (significant in APAP 
study: p<0.004; significant in Cp study: p<0.0014) using GraphPad Prism 6 (GraphPad Software 
Inc., CA). Logistic regression models were used to evaluate associations of all three candidate 
miRNA biomarkers as well as KIM-1 with the odds of AKI, and to estimate area under the 
receiver operator curve (AUC-ROC). Regression models were adjusted for age and sex. 
Spearman correlation analysis (ρ and corresponding p-value) was performed to assess 
correlation between all biomarkers using data from all patients at all time points. Statistical 
analyses were performed using Stata 13.0 (StataCorp, College Station, TX).  
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RESULTS  
Detection of APAP-induced AKI in a cross-sectional study using KIM-1 and candidate 
miRNAs 
Three groups of patients, 43 with APAP overdose and AKI and 27 without a clinical diagnosis of 
AKI, as well as 65 healthy volunteers were enrolled in the cross-sectional study (Table 1). Since 
APAP is primarily a liver toxicant, all APAP-overdosed (OD) patients had liver injury diagnosed 
by ~100-fold increased levels of alanine aminotransferase as compared to healthy volunteers 
(Table 1). Urinary levels of KIM-1, miR-21, -200c, and -423 were significantly (adjusted p-value 
cutoff: p<0.004) higher in both APAP-OD patients with AKI compared to healthy controls and in 
APAP-OD patients without AKI diagnosis compared to healthy controls (Figure1A and B). 
Among patients with APAP-OD, higher urinary concentrations of each biomarker were 
associated with higher odds of AKI (Table 2). After adjustment for age and gender, every 
doubling of miR-21 concentration was associated with 1.31-fold higher odds of AKI (95%CI: 
1.07, 1.60; p<0.01). Every doubling of KIM-1 concentration was associated with 3.2-fold higher 
odds of AKI, (95% CI: 1.74, 5.82; p<0.001). In predictive performance analyses, KIM-1 had the 
highest area under the ROC curve (AUC=0.84, 95%CI: 0.74, 0.94) while miR-21, -200c and -
423 had ROC-AUC’s between 0.64-0.71. A combination of miRNAs with KIM-1 did not 
substantively increase the predictive performance, as assessed by ROC-AUCs (Table 2).  
 
Performance of KIM-1 and candidate miRNAs in a longitudinal study of Cp-induced AKI  
To evaluate early diagnostic and predictive capabilities we next measured candidate miRNAs 
and KIM-1 in a longitudinal cohort of patients (n=106) with mesothelioma undergoing 
cytoreductive surgery with intraoperative Cp before and after Cp administration (Table 3). MiR-
21, -200c, and 423 were high in mesothelioma patients at baseline before Cp-treatment as 
compared to levels from healthy, non-cancer patients from the APAP study (Suppl. Figure 1). 
After Cp treatment, we found that miR-21, -200c, -423 as well as KIM-1 significantly increased 
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(adjusted p-value cutoff: p<0.0014) in urine compared to levels before the treatment with each 
biomarker being high in patients with AKI diagnosis but also in patients without clinically proven 
AKI (Figure 2). At any given time point, however, none of the biomarkers were significantly 
different between patients with and without AKI and concentrations of biomarkers were not 
associated with the odds of AKI (Table 4). All miRNAs correlated highly with each other, 
whereas the correlation of miRNAs was weak with KIM-1 SCr. The correlation of KIM-1 with SCr 
was also weak (Table 5). 
 
Expression patterns of miR-21, -200c and -423 in the human kidney 
In an attempt to investigate the expression patterns of the candidate miRNAs in human kidney 
we conducted in situ hybridization based miRNA localization in kidney biopsy samples from 
patients with clinical diagnosis of acute tubular necrosis (ATN) – pathologically characterized by 
tubular dilatation, cellular debris in tubular lumen and descendent tubular epithelia (Figure 3). 
Biopsy samples from patients without evidence of kidney damage served as controls (normal). 
miR-21 was not detectable in normal tissue, but found to increase significantly and co-localize 
with injured areas (Figure 3, black arrows). miR-200c was neither seen in controls nor in ATN 
kidneys, whereas miR-423 showed a very strong expression in both (Figure 3).  
 
Release of miR-21, -200c and -423 by human proximal tubular epithelial cells in response 
to toxicity 
Within the nephron the primary target of Cp and APAP toxicity are the proximal tubules and 
therefore miRNA expressions were measured in human proximal tubular epithelial cells 
(HPTECs) after treatment with Cp and 4-aminophenol (4-AP; degradation product of APAP). 
Following 24h of exposure to 85 µM of Cp and 100 µM of 4-AP the viability of the cells was 
decreased by approximately 50% and all three miRNAs significantly (p<0.05) increased in the 
cell culture media (Figure 4A and B). In the cells itself, the three miRNAs were minimal 
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decreased after Cp treatment (Figure 4C). The increase in medium not only mimics the in vivo 
findings and strengthens the hypothesis of kidney proximal tubular epithelial cells to be the 
source for miR-21, -200c and -423 releases in urine after kidney toxicity but also demonstrates 
the utility of these candidate miRNAs for screening nephrotoxic agents in vitro.  
 
Mechanistic implication of miR-21, -200c and -423 
MiRNAs function as intracellular regulators of gene expression, thus we hypothesized that the 
urinary miRNA profile might reflect affected pathways in the injured kidney. To test this 
hypothesis, Ingenuity Pathway Analysis (IPA) was used to find mRNA targets for miR-21, -200c 
and -423. In total, 1102 mRNA targets were identified mostly associated with pathways also 
known to be perturbed in different pathological conditions in the kidney (Figure 5A). The top 
pathway and associated pathological condition was found to be MYC-mediated apoptosis 
signaling and renal necrosis/cell death, respectively. In addition, a deeper insight into the targets 
associated with renal necrosis/cell death as major feature of AKI, revealed that miR-21, -200c 
and -423 have several overlapping targets including genes well-known in apoptosis like cyclin-
dependent kinase inhibitor 1 (CDKN1A, p21) or B-cell lymphoma 2 (Bcl-2) (Figure 5B).  
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DISCUSSION    
Using a multi-dimensional approach to examine the association of candidate biomarkers with 
drug-induced AKI, we evaluated urinary KIM-1, miR-21, -200c and -423 among AKI patients, 
enrolled in a cross-sectional as well as longitudinal study. All four biomarkers were higher in 
patients with APAP overdose, relative to healthy subjects and were highest among patients with 
APAP overdose and diagnosed AKI. In longitudinal analyses, all biomarkers were elevated post 
Cp treatment, regardless of future AKI status. 
The poor performance of urinary miRNAs and KIM-1 to predict AKI may reflect the inadequacy 
of a SCr-based definition for AKI (Waikar et al., 2012).  Although in preclinical studies renal 
histopathological examination is the gold standard for AKI diagnosis, in clinical assessments 
SCr remains widely used. In fact, moderate performances of new AKI biomarker candidates are 
frequently seen in clinical studies, where AKI is mostly defined based on increased SCr levels 
(Vanmassenhove et al., 2013). Several studies have demonstrated that patients who were SCr 
negative but biomarker positive are at risk for short- as well as long term morbidity and mortality 
(Coca et al., 2014;  Haase et al., 2011). Haase et al. (2012) suggested to term this condition 
subclinical AKI, because it is not clinically detectable with existing routine diagnostics (SCr, 
blood urea nitrogen) however, tubular damage markers such as KIM-1 and NGAL suggest injury 
(Haase et al., 2012).  
In a preclinical study, both miR-21 and KIM-1 accurately reflected AKI diagnosed by 
histopathology but not when diagnosed by SCr (Suppl. Figure 2; Pavkovic et al., 2014 and 
2015). In clinical settings renal biopsies are not readily available, thus the evaluation of novel 
biomarkers becomes hindered by the inadequacy of SCr-based definitions of the outcome. 
Finding a solution to this paradox in clinical AKI biomarker evaluation is challenging. However, 
in the case of drug-induced AKI, the treatment with the nephrotoxic drug per se can be used for 
comparison. 
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Our results confirmed previous reports that KIM-1 has high sensitivity and specificity for tubular 
injury. A meta-analysis including data from 2979 patients concluded that urinary KIM-1 may be a 
promising biomarker for early detection of AKI also in clinical settings (Shao et al., 2014). A 
recently published study using a very small number of patients (n=22) with solid tumors 
receiving Cp treatment showed a comparable increase of KIM-1 in urine after treatment, as 
seen here, whereas SCr was not increased (Tekce et al., 2015). The exploration of KIM-1’s 
function revealed interesting features involved in phagocytosis and regeneration (Ichimura et al., 
2008;  Yang et al., 2015), but limited information was added to the mechanism of initiation of 
AKI.  
In contrast, miRNAs bear the potential to fill this gap since it is estimated that over 50% of all 
protein-coding genes are regulated by miRNAs (Krol, et al., 2010). Applying Ingenuity Pathway 
Analysis for the three candidate miRNAs studied here, the top pathological kidney conditions 
found to be associated with the targets was renal necrosis highlighting the previously mentioned 
possibility of urinary miRNA profiles to mirror molecular perturbations in the kidney. MiR-21 has 
been extensively explored since it is ubiquitously expressed in mammalian organs; it is enriched 
in the kidney where it is involved in diverse physiological as well as pathophysiological 
processes (Landgraf et al., 2007;  Ma and Qu, 2013). In the context of AKI, miR-21 is described 
as a negative regulator in the apoptosis of tubular epithelial cells but also as involved in 
progression of fibrosis via SMADs after TGFβ activation (Li et al., 2013). In a mouse model of 
Alport nephropathy it was shown that since miR-21 is further involved in metabolism and FA 
oxidation, inhibition of miR-21 probably enhanced PPARα/RXR activity and improved 
mitochondrial function. Thus it was deemed protective against TGF-β-induced fibrogenesis and 
inflammation in kidneys (Gomez et al., 2015). MiR-200c has been mainly investigated in the 
context of cancer where it was found to regulate epithelial–mesenchymal transition via 
downregulation of ZEB1 and AKT resulting in an upregulation of E-cadherin (Bracken et al., 
2015;  Wang et al., 2013). In addition, miR-200c is involved in cell growth and cell cycle 
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progression by suppressing the expression of CDK2 in renal carcinoma cell lines and xenografts 
(Wang et al., 2015). MiR-423 has been less well-studied but has been shown to increase 
proliferation and cell growth by targeting Trefoil factor 1 and p21 in gastric and hepatocellular 
cancer, respectively (Lin et al., 2011;  Liu et al., 2014). Furthermore, miR-423 is part of a miRNA 
signature associated with lupus nephritis (Te et al., 2010). Overall, target prediction analysis 
and current knowledge about the function of the three miRNAs support our hypothesis of urinary 
miRNAs profiles as reflection of intrarenal processes.  
Using human kidney biopsy samples, miR-423 was found expressed in the whole kidney cortex 
i.e. in tubular and glomerular structures whereas miR-200c could not be detected and miR-21 
seemed to be expressed in injured areas of the kidney from patients with ATN. An expression in 
normal human kidneys was shown previously for miR-21 and -200c using PCR (Bao et al., 
2014), thus the lack of detection here could be due to the low technical sensitivity of in situ 
hybridization. Expression of all three miRNAs was detected in HPTECs. For miR-21, contrary to 
the in situ hybridization results, decreased expression was seen in HPTECs after treatment with 
Cp. This discrepancy could be due to the in vitro system per se or the different kind of AKI (ATN 
after allograft rejection) in the kidney biopsy samples. However, we found all three miRNAs 
increased in cell medium after Cp or 4-AP treatment, probably mimicking the in vivo situation. 
Our study has several limitations. First, the longitudinal cohort consisted of patients with 
malignant mesothelioma. As such, an impact of concomitant cancer, rather than the Cp-
treatment per se, on the miRNA profile in urine cannot be excluded. In fact, miR-21 expression 
in cancerous tissue was described as part of a 6-miRNA signature to predict survival in patients 
with malignant mesothelioma (Kirschner et al., 2015). A direct comparison of all biomarker 
profiles in urine from both studies demonstrated high levels of miR-21, -200c and -423 in cancer 
patients (Suppl. Figure 1). Second, miRNA candidates were selected based on a cross-
sectional discovery approach with healthy volunteers vs. AKI patients from the intensive care 
unit having different etiologies. Since AKI is a clinical condition with various etiologies the 
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existence of one single, universal AKI biomarker seems unlikely. A more focused discovery 
approach using a case-control cohort of patients with drug-induced kidney toxicity has the 
potential to yield more sensitive and specific biomarkers for drug-induced AKI.  
In summary, we show that KIM-1 along with miR-21, -200c and -423 can be non-invasive as 
well as specific urinary biomarkers for the detection of drug-induced AKI in patients. Based on 
their kidney expression and target analysis, miR-21, -200c, and -423 could add information 
about the affected molecular pathways in the kidney during AKI.    
 
  
Page 16 of 36Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 17 of 31 
SUPPLEMENTARY MATERIAL 
1) Supplementary Figure 1 
• Urinary levels of miR-21, -200c, -423 and KIM-1 from both studies 
2) Supplementary Figure 2 
• Literature example: inaccuracy of serum creatinine as gold standard 
3) Supplementary Figure 3 
• Technical controls for qRT-PCR 
 
FUNDING INFORMATION 
MP is a recipient of a research fellowship from the Deutsche Forschungsgesellschaft (DFG).The 
Specialized Histopathology Core at the Dana-Farber/Harvard Cancer Center is supported in 
part by the NCI Cancer Center Support Grant # NIH 5 P30 CA06516. DJA would like to 
acknowledge additional support from the Wellcome Trust and the Royal Society International 
Exchange Scheme. Work in the Vaidya laboratory was supported by Outstanding New 
Environmental Sciences (ONES) award from NIH/NIEHS (ES017543), Innovation in Regulatory 
Science Award from Burroughs Wellcome Fund (BWF-1012518) and a collaborative research 
agreement with Biogen (A24378). 
 
ACKNOWLEDGEMENTS 
We thank Dr. Susanne Ramm, Cory Gerlach and Vidya Chandrasekaran for extraordinary 
scientific and technical support. Further, we thank Dana-Farber/Harvard Cancer Center in 
Boston, MA, for the use of the Specialized Histopathology Core, which provided sectioning and 
H&E staining services. Authors LH, MP and DJA would like to acknowledge support from the 
Medical Research Council.  
 
STATEMENT OF COMPETING FINANCIAL INTERESTS: None 
Page 17 of 36 Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 18 of 31 
REFERENCES 
 
Adler, M., Ramm, S., Hafner, M., Muhlich, J. L., Gottwald, E. M., Weber, E., Jaklic, A., Ajay, A. 
K., Svoboda, D., Auerbach, S., Kelly, E. J., Himmelfarb, J., and Vaidya, V. S. (2015). A 
Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. Journal of the American 
Society of Nephrology : JASN doi: 10.1681/ASN.2015010060. 
Bao, H., Hu, S., Zhang, C., Shi, S., Qin, W., Zeng, C., Zen, K., and Liu, Z. (2014). Inhibition of 
miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy. 
Biochemical and biophysical research communications 444(4), 455-60. 
Bracken, C. P., Khew-Goodall, Y., and Goodall, G. J. (2015). Network-Based Approaches to 
Understand the Roles of miR-200 and Other microRNAs in Cancer. Cancer research 75(13), 
2594-9. 
Coca, S. G., Garg, A. X., Thiessen-Philbrook, H., Koyner, J. L., Patel, U. D., Krumholz, H. M., 
Shlipak, M. G., Parikh, C. R., and Consortium, T.-A. (2014). Urinary biomarkers of AKI and 
mortality 3 years after cardiac surgery. Journal of the American Society of Nephrology : JASN 
25(5), 1063-71. 
Dieterle, F., and Sistare, F. (2010). Biomarkers of Acute Kidney Injury. In Biomarkers: In 
Medicine, Drug Discovery, and Enviromental Health (V. S. Vaidya, and J. V. Bonventre,  Eds.) 
doi, pp. 237-263. Wiley & Sons, Inc. 
EMA (2009). Final conclusions of the pilot joint EMEA/FDA VXDA experience on qualification of 
nephrotoxicity biomarkers. www.emea.europa.eu Doc.ref. EMEA/679719/2008 Rev. 
1(Committee for medicinal products for human use). 
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, 
N., Xin, C., Newitt, R., Pandya, S., Xia, T. H., Liu, X., Borza, D. B., Grafals, M., Shankland, S. J., 
Himmelfarb, J., Portilla, D., Liu, S., Chau, B. N., and Duffield, J. S. (2015). Anti-microRNA-21 
oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. 
The Journal of clinical investigation 125(1), 141-56. 
Page 18 of 36Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 19 of 31 
Haase, M., Devarajan, P., Haase-Fielitz, A., Bellomo, R., Cruz, D. N., Wagener, G., Krawczeski, 
C. D., Koyner, J. L., Murray, P., Zappitelli, M., Goldstein, S. L., Makris, K., Ronco, C., 
Martensson, J., Martling, C. R., Venge, P., Siew, E., Ware, L. B., Ikizler, T. A., and Mertens, P. 
R. (2011). The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute 
kidney injury: a multicenter pooled analysis of prospective studies. Journal of the American 
College of Cardiology 57(17), 1752-61. 
Haase, M., Kellum, J. A., and Ronco, C. (2012). Subclinical AKI--an emerging syndrome with 
important consequences. Nature reviews. Nephrology 8(12), 735-9. 
Ichimura, T., Asseldonk, E. J., Humphreys, B. D., Gunaratnam, L., Duffield, J. S., and 
Bonventre, J. V. (2008). Kidney injury molecule-1 is a phosphatidylserine receptor that confers a 
phagocytic phenotype on epithelial cells. The Journal of clinical investigation 118(5), 1657-68. 
Jensen, O. N. (2004). Modification-specific proteomics: characterization of post-translational 
modifications by mass spectrometry. Current opinion in chemical biology 8(1), 33-41. 
Kirschner, M. B., Cheng, Y. Y., Armstrong, N. J., Lin, R. C., Kao, S. C., Linton, A., Klebe, S., 
McCaughan, B. C., van Zandwijk, N., and Reid, G. (2015). MiR-score: a novel 6-microRNA 
signature that predicts survival outcomes in patients with malignant pleural mesothelioma. 
Molecular oncology 9(3), 715-26. 
Krol, J., Loedige, I., and Filipowicz, W. (2010). The widespread regulation of microRNA 
biogenesis, function and decay. Nature reviews. Genetics 11(9), 597-610. 
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., 
Kamphorst, A. O., Landthaler, M., Lin, C., Socci, N. D., Hermida, L., Fulci, V., Chiaretti, S., Foa, 
R., Schliwka, J., Fuchs, U., Novosel, A., Muller, R. U., Schermer, B., Bissels, U., Inman, J., 
Phan, Q., Chien, M., Weir, D. B., Choksi, R., De Vita, G., Frezzetti, D., Trompeter, H. I., 
Hornung, V., Teng, G., Hartmann, G., Palkovits, M., Di Lauro, R., Wernet, P., Macino, G., 
Rogler, C. E., Nagle, J. W., Ju, J., Papavasiliou, F. N., Benzing, T., Lichter, P., Tam, W., 
Brownstein, M. J., Bosio, A., Borkhardt, A., Russo, J. J., Sander, C., Zavolan, M., and Tuschl, T. 
Page 19 of 36 Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 20 of 31 
(2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 
129(7), 1401-14. 
Li, Y. F., Jing, Y., Hao, J., Frankfort, N. C., Zhou, X., Shen, B., Liu, X., Wang, L., and Li, R. 
(2013). MicroRNA-21 in the pathogenesis of acute kidney injury. Protein & cell 4(11), 813-9. 
Lin, J., Huang, S., Wu, S., Ding, J., Zhao, Y., Liang, L., Tian, Q., Zha, R., Zhan, R., and He, X. 
(2011). MicroRNA-423 promotes cell growth and regulates G(1)/S transition by targeting 
p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis 32(11), 1641-7. 
Liu, J., Wang, X., Yang, X., Liu, Y., Shi, Y., Ren, J., and Guleng, B. (2014). miRNA423-5p 
regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells. 
Cancer letters 347(1), 98-104. 
Ma, L., and Qu, L. (2013). The function of microRNAs in renal development and 
pathophysiology. Journal of genetics and genomics = Yi chuan xue bao 40(4), 143-52. 
McDonald, J. S., Milosevic, D., Reddi, H. V., Grebe, S. K., and Algeciras-Schimnich, A. (2011). 
Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57(6), 833-
40. 
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., 
and Acute Kidney Injury, N. (2007). Acute Kidney Injury Network: report of an initiative to 
improve outcomes in acute kidney injury. Critical care 11(2), R31. 
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. 
L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., Lin, D. W., Urban, N., Drescher, C. W., 
Knudsen, B. S., Stirewalt, D. L., Gentleman, R., Vessella, R. L., Nelson, P. S., Martin, D. B., and 
Tewari, M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. 
Proceedings of the National Academy of Sciences of the United States of America 105(30), 
10513-8. 
Mraz, M., Malinova, K., Mayer, J., and Pospisilova, S. (2009). MicroRNA isolation and stability in 
stored RNA samples. Biochemical and biophysical research communications 390(1), 1-4. 
Page 20 of 36Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 21 of 31 
Murray, P. T., Mehta, R. L., Shaw, A., Ronco, C., Endre, Z., Kellum, J. A., Chawla, L. S., Cruz, 
D., Ince, C., Okusa, M. D., and workgroup, A. (2014). Potential use of biomarkers in acute 
kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality 
Initiative consensus conference. Kidney international 85(3), 513-21. 
Pavkovic, M., Riefke, B., Frisk, A. L., Groticke, I., and Ellinger-Ziegelbauer, H. (2015). 
Glomerulonephritis-Induced Changes in Urinary and Kidney MicroRNA Profiles in Rats. Toxicol 
Sci 145(2), 348-59. 
Pavkovic, M., Riefke, B., Gutberlet, K., Raschke, M., and Ellinger-Ziegelbauer, H. (2014). 
Comparison of the MesoScale Discovery and Luminex multiplex platforms for measurement of 
urinary biomarkers in a cisplatin rat kidney injury model. J Pharmacol Toxicol Methods 69(2), 
196-204. 
Ramachandran, K., Saikumar, J., Bijol, V., Koyner, J. L., Qian, J., Betensky, R. A., Waikar, S. 
S., and Vaidya, V. S. (2013). Human miRNome profiling identifies microRNAs differentially 
present in the urine after kidney injury. Clin Chem 59(12), 1742-52. 
Saikumar, J., Hoffmann, D., Kim, T. M., Gonzalez, V. R., Zhang, Q., Goering, P. L., Brown, R. 
P., Bijol, V., Park, P. J., Waikar, S. S., and Vaidya, V. S. (2012). Expression, circulation, and 
excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 
129(2), 256-67. 
Shao, X., Tian, L., Xu, W., Zhang, Z., Wang, C., Qi, C., Ni, Z., and Mou, S. (2014). Diagnostic 
value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PloS one 9(1), 
e84131. 
Susantitaphong, P., Cruz, D. N., Cerda, J., Abulfaraj, M., Alqahtani, F., Koulouridis, I., Jaber, B. 
L., and Acute Kidney Injury Advisory Group of the American Society of, N. (2013). World 
incidence of AKI: a meta-analysis. Clinical journal of the American Society of Nephrology : 
CJASN 8(9), 1482-93. 
Page 21 of 36 Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 22 of 31 
Taber, S. S., and Pasko, D. A. (2008). The epidemiology of drug-induced disorders: the kidney. 
Expert opinion on drug safety 7(6), 679-90. 
Te, J. L., Dozmorov, I. M., Guthridge, J. M., Nguyen, K. L., Cavett, J. W., Kelly, J. A., Bruner, G. 
R., Harley, J. B., and Ojwang, J. O. (2010). Identification of unique microRNA signature 
associated with lupus nephritis. PloS one 5(5), e10344. 
Tekce, B. K., Uyeturk, U., Tekce, H., Uyeturk, U., Aktas, G., and Akkaya, A. (2015). Does the 
kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage? Annals of clinical 
biochemistry 52(Pt 1), 88-94. 
Uchino, S., Kellum, J. A., Bellomo, R., Doig, G. S., Morimatsu, H., Morgera, S., Schetz, M., Tan, 
I., Bouman, C., Macedo, E., Gibney, N., Tolwani, A., Ronco, C., Beginning, and Ending 
Supportive Therapy for the Kidney, I. (2005). Acute renal failure in critically ill patients: a 
multinational, multicenter study. Jama 294(7), 813-8. 
Vaidya, V. S., Ferguson, M. A., and Bonventre, J. V. (2008). Biomarkers of acute kidney injury. 
Annual review of pharmacology and toxicology 48, 463-93. 
Vanmassenhove, J., Vanholder, R., Nagler, E., and Van Biesen, W. (2013). Urinary and serum 
biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association 28(2), 254-73. 
Waikar, S. S., Betensky, R. A., Emerson, S. C., and Bonventre, J. V. (2012). Imperfect gold 
standards for kidney injury biomarker evaluation. Journal of the American Society of Nephrology 
: JASN 23(1), 13-21. 
Wang, X., Chen, X., Han, W., Ruan, A., Chen, L., Wang, R., Xu, Z., Xiao, P., Lu, X., Zhao, Y., 
Zhou, J., Chen, S., Du, Q., Yang, H., and Zhang, X. (2015). miR-200c Targets CDK2 and 
Suppresses Tumorigenesis in Renal Cell Carcinoma. Molecular cancer research : MCR 13(12), 
1567-77. 
Page 22 of 36Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 23 of 31 
Wang, X., Chen, X., Wang, R., Xiao, P., Xu, Z., Chen, L., Hang, W., Ruan, A., Yang, H., and 
Zhang, X. (2013). microRNA-200c modulates the epithelial-to-mesenchymal transition in human 
renal cell carcinoma metastasis. Oncology reports 30(2), 643-50. 
Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., Huang, K. H., Lee, M. J., Galas, D. J., and 
Wang, K. (2010). The microRNA spectrum in 12 body fluids. Clin Chem 56(11), 1733-41. 
Yang, L., Brooks, C. R., Xiao, S., Sabbisetti, V., Yeung, M. Y., Hsiao, L. L., Ichimura, T., 
Kuchroo, V., and Bonventre, J. V. (2015). KIM-1-mediated phagocytosis reduces acute injury to 
the kidney. The Journal of clinical investigation 125(4), 1620-36. 
  
Page 23 of 36 Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 24 of 31 
FIGURE LEGENDS 
Figure 1 Urinary profiles of kidney injury molecule-1 (KIM-1), miR-21, miR-200c and miR-
423 in acetaminophen-induced kidney injury. Levels of miR-21, -200c and -423 and KIM-1 
were measured in urine from healthy controls (n=65) as well as in patients with an 
acetaminophen (APAP) overdose (OD; n=70). Within latter group approximately 62% of the 
patients developed clinically proven AKI (50 % increase in serum creatinine). MiRNA levels and 
KIM-1 concentrations were normalized to urinary creatinine. A) Both data sets were log2 
transformed and presented as box plots (median with inter quartile range) with 5th and 95th 
percentile as whiskers. T-test was used for p-value calculation: * p<0.004. B) Table with 
absolute levels as medians (interquartile range) of arbitrary miRNA levels (x10-2; 2–∆Ct 
normalized by urinary creatinine) or absolute KIM-1 concentration (pg/mg urinary creatinine). 
UCr, urinary creatinine. 
 
Figure 2 KIM-1, miR-21, -200c and -423 increase in the longitudinal cisplatin (Cp) cohort 
in patients with and without clinical AKI. Levels of miR-21, -200c and -423 as well as KIM-1 
were measured in urine from patients (n=108) before (Pre) and on nine following time points 
after Cp treatment grouping patients based on their serum creatinine dependent AKI status. 
Data sets were normalized to urinary creatinine, log2 transformed and presented as box plots 
(median with 25th and 75th percentiles) with 5th and 95th percentile as whiskers. T-test was used 
for p-value calculation to compare to the group baseline as well as within the two groups: * 
p<0.0014. Broken lines represent the median level before treatment of No AKI developers. 
 
Figure 3 Localization of miR-21, -200c and 423 in human kidney biopsies from patients 
with acute tubular necrosis. Pathological examination of the biopsy samples was performed 
with standard H&E stained sections. Using in situ hybridization, the expression patterns of miR-
21, -200c and -423 were assessed in kidney biopsies from normal controls and patients 
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diagnosed with acute tubular necrosis (ATN). In situ hybridization settings were proven with U6 
as positive control, having an abundant nuclear expression, and a scrabbled probe, not 
complementary to any known miRNA sequence, used as negative control. Star, tubular casts; 
arrow, positive miR-21 signal. For in situ: blue, positive probe staining; pink, counter staining; 
H&E pictures taken with ×10 others with 20x objective; representative images of n=3 controls 
and n=3 ATN patients. 
 
Figure 4 Human proximal tubular epithelial cells release miR-21, -200c and -423 following 
toxicity. Human proximal tubular epithelial cells (HPTECs) were treated with cisplatin and 4-
aminophenol (APAP degradation product) for 24h followed by measurement of viability and 
miR-21, -200c and -423. (A) Dose-response curves after 24h treatment with 0, 10, 31.6, 100, 
316 and 1000 µM cisplatin and 4-aminophenol, respectively. Data is presented as means with 
standard deviation of percentage viability compared to the 0.5% DMSO treated control with 
fitted non-linear dose-response curves (n=3 to 6 replicates). Levels of miR-21, -200c and -423 
in the medium supernatant (B) as well as in the cells (C) after 24h treatment with 85 µM cisplatin 
and 100 µM 4-aminophenol, respectively. Data is presented as mean with standard deviation 
(n=3-4) of relative quantities (RQ, 2-∆∆Ct). 1-way ANOVA with Dunnett’s test was used for p-
value calculation: * p<0.05, ** p<0.01, and *** p<0.001.  
 
Figure 5 Target prediction analysis of miRNA biomarker candidates. Ingenuity Pathway 
Analysis (IPA) was used to identify mRNA targets of the three miRNAs (experimentally verified 
and highly predicted based on sequence complementarity). A) Within the pool of 1102 identified 
targets, IPA’s Core Analysis tool revealed associated pathways and pathological conditions. 
Bases on the ratio of genes found in the pool vs. genes related to the specific pathways or 
diseases, top 5 associated pathways and pathological condition of the kidney were listed. B) All 
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49 targets associated with Renal Necrosis/Cell Death were plotted as network with the three 
miRNAs revealing overlapping targets as well as a complex interaction between the targets.  
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Table 1 Demographic and clinical characteristics of patients from the cross-sectional APAP 
cohort 
Characteristic 
Healthy volunteers 
(n = 65) 
APAP-OD 
(n = 27) 
APAP-OD with AKI  
(n = 43) 
Age, years 34.9 ± 9.8 39.3 ± 15.9 39.8 ± 13.4 
Sex, female 37 (56.9%) 17 (62.9%) 24 (55.8%) 
D/LT N/A 3 (11.1%) 19 (44.2%) 
ALT activity (U/L) 30 (24 – 33) 3597 (2251 – 6226) 4601 (2188 – 7673) 
SCr (mg/dL) N/A 0.62 (0.54 – 0.70) 2.44 (1.33 – 3.04) 
Data are means ± SD, n (%) or medians (25th-75th interquartile range); APAP, acetaminophen; 
OD, overdose; ALT, alanine aminotransferase; SCr, serum creatinine; D/LT, deceased/ liver 
transplantation 
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Table 2 Cross-sectional associations of biomarkers with AKI, among participants with APAP-OD 
Biomarker, 
per doubling 
AUC†  
(95% CI) 
OR unadjusted 
(95% CI) 
ORa adjusted 
(95% CI) 
AUC† KIM-1 combined 
 (95% CI) 
miR-21 0.71 (0.58, 0.83) 1.30 (1.07, 1.59)** 1.31 (1.07, 1.60)** 0.84 (0.73, 0.94) 
miR-200c 0.64 (0.51, 0.77) 1.27 (1.04,1.55)* 1.27 (1.04, 1.57)* 0.85 (0.76, 0.95) 
miR-423 0.68 (0.56, 0.81) 1.29 (1.07, 1.56)** 1.29 (1.07, 1.56)** 0.84 (0.74, 0.95) 
KIM-1 0.84 (0.74, 0.94) 3.08 (1.71, 5.56)*** 3.18 (1.74, 5.82)*** -/- 
† Area under the curve for ROC curve; Odds ratio presented per doubling of each biomarker. 
aOdds ratio adjusted for age and gender; ‡ Adjusted for KIM-1 concentration and covariates in a. 
***p<0.001;**p<0.01;*p<0.05  
Page 28 of 36Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Page 29 of 31 
Table 3 Baseline demographic and clinical characteristics of patients from the longitudinal Cp 
cohort by AKI status  
Characteristic 
No clinical AKI 
(n = 61) 
AKI Stage 1 
(n = 30) 
AKI Stage 2&3 
(n = 15) 
Age, years 62.5 ± 10.5 64.9 ± 10.9 67.5 ± 10.6 
Sex, female 18 (29.5%) 4 (13.3%) 3 (20%) 
Race, White  57 (93.4%) 29 (96.7%) 15 (100%) 
Race, Black  1 (1.6%) 1 (3.3%) N/A 
Data are mean ± SD or n (%); AKI Stage 1, 50-100% increase of SCr over baseline at any time 
point; AKI Stage 2&3, >100% increase of SCr over baseline at any time point. 
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Table 4 Association of biomarker concentration doublings at 4h, 8h, 12h and 24h with AKI 
status (any stage) at 48 hours 
Biomarker Time point OR (95% CI) p-value 
miR-21 
4h 0.92 (0.75, 1.12) 0.399 
8h 1.05 (0.87, 1.27) 0.612 
12h 1.20 (0.99, 1.45) 0.060 
24h 1.13 (0.94, 1.37) 0.200 
miR-200 
4h 0.79 (0.65, 0.97) 0.022 
8h 0.94 (0.76, 1.17) 0.575 
12h 1.18 (0.96, 1.45) 0.120 
24h 1.06 (0.87, 1.30) 0.558 
miR-423 
4h 0.79 (0.65, 0.97) 0.025 
8h 0.99 (0.81, 1.21) 0.929 
12h 1.13 (0.93, 1.38) 0.203 
24h 1.13 (0.91, 1.39) 0.267 
KIM-1 
4h 1.10 (0.98, 1.23) 0.098 
8h 1.06 (0.94, 1.20) 0.341 
12h 0.85 (0.69, 1.05) 0.140 
24h 0.89 (0.73, 1.10) 0.288 
SCr 
4h 1.18 (0.40, 3.54) 0.762 
8h 1.49 (0.50, 4.43) 0.478 
12h 3.35 (1.03, 10.95) 0.045 
24h 5.77 (2.01, 16.58) 0.001 
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Table 5 Correlation of all biomarkers over all groups and time points in the cisplatin cohort 
   SCr KIM-1 miR-21 miR-200c miR-423 
SCr ρ 1     
 p-value      
KIM-1 ρ 0.1312 1    
 p-value <0.001     
miR-21 ρ -0.016 0.2388 1   
 p-value 0.6218 <0.001    
miR-200c ρ -0.0802 0.1381 0.8331 1  
 p-value 0.0132 <0.001 <0.001   
miR-423 ρ -0.1381 0.1322 0.6989 0.8556 1 
 p-value <0.0001 <0.001 <0.001 <0.001  
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Figure 1 Urinary profiles of kidney injury molecule-1 (KIM-1), miR-21, miR-200c and miR-423 in 
acetaminophen-induced kidney injury.  
98x108mm (300 x 300 DPI)  
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Figure 2 KIM-1, miR-21, -200c and -423 increase in the longitudinal cisplatin (Cp) cohort in patients with 
and without clinical AKI.  
127x217mm (300 x 300 DPI)  
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Figure 3 Localization of miR-21, -200c and 423 in human kidney biopsies from patients with acute tubular 
necrosis.  
138x214mm (300 x 300 DPI)  
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Figure 4 Human proximal tubular epithelial cells release miR-21, -200c and -423 following toxicity.  
194x425mm (300 x 300 DPI)  
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Figure 5 Target prediction analysis of miRNA biomarker candidates.  
101x123mm (300 x 300 DPI)  
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